2nd International HIV/Viral Hepatitis Co-infection Meeting

“A Cure For All”

HIV / Viral hepatitis: Antiviral therapy development and access

Sheraton Vancouver Wall Centre
July 17-18, 2015 | Vancouver, Canada

www.coinfectionmeeting.com | #ACureForAll
WELCOME TO VANCOUVER

We are pleased to be presenting the 2nd International HIV/Viral Hepatitis Co-infection Meeting, July 17-18, 2015, an official event of the 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015), in beautiful Vancouver, BC, Canada.

This year’s meeting will build momentum towards expanding HCV treatment access globally for HIV and viral hepatitis co-infected persons. We will review the most up-to-date science and attempt to address the significant gaps in our current understanding and response. By bringing together national and international stakeholders to develop a strategic research and policy agenda, we hope to address the growing global concern around HIV and viral hepatitis co-infections and support the development of effective partnerships and public engagement around this emerging public health issue.

The 2nd International HIV/Viral Hepatitis Co-infection Meeting is being organized by the CIHR Canadian HIV Trials Network (CTN) and the International AIDS Society (IAS), and sponsored by Abbvie, Bristol Meyers Squibb, Gilead, Merck and supported by the ANRS (France REcherche Nord & sud Sida-hiv Hépatites), Canadian Institutes of Health Research (CIHR), the European AIDS Clinical Society (EACS), and the Réseau sida et maladies infectieuses (FRSQ).

We hope that you find the meeting informative and productive, and enjoy Vancouver’s natural beauty.

Warm regards,

Marina B. Klein, MD, MSc, FRCP(C)  Jürgen Rockstroh, MD
Conference Co-Chair  Conference Co-Chair

ORGANIZING COMMITTEE

Marina Klein
(Co-chair)
McGill University, CIHR Canadian HIV Trials Network,
Montreal, Canada

Jürgen Rockstroh
(Co-chair)
Oberarzt an der Medizinischen Universitätsklinik, Bonn-Venusberg, Bonn, Germany

Mark Sulkowski
(Convener of HCV therapeutic development theme)
Viral Hepatitis Center, John Hopkins, Baltimore, USA

Curtis Cooper
(Convener of HCV therapeutic development theme)
The University of Ottawa, Ottawa, Canada

Gail Matthews
(Convener of Complex issues in HCV theme)
Kirby Institute, University of New South Wales, Sydney, Australia

Sanjay Bhagani
(Convener of Complex issues in HCV theme)
Royal Free Hospital, London, UK

Tracy Swan
(Convener of HCV access theme)
Treatment Action Group, New York, USA

Isabelle Andrieux-Meyer
(Convener of HCV access theme)
MSF, Geneva, Switzerland

Jordan Feld
(Convener of HBV prevention and management)
University of Toronto, Toronto, Canada

Marion Peters
(Convener of HBV therapeutic development theme)
University of California, San Francisco, USA

Greg Dore
(Convener of treatment in special populations theme)
Kirby Institute, University of New South Wales, Sydney, Australia

Karine Lacombe
(Convener of Epidemiology and disease burden theme)
Hôpital Saint-Antoine, Paris, France

Anchalee Avihingsanon
(Convener of Epidemiology and disease burden theme)
HIV-NAT, Bangkok, Thailand
The International HIV/Viral Hepatitis Co-Infection Meeting officially begins on Friday, July 17, 2015 when registration opens at 8 a.m.

Conference Venue
Sheraton Vancouver Wall Centre
1088 Burrard Street
Vancouver, BC V6Z 2R9
Phone: (604) 331-1000
Web: www.sheratonvancouver.com

Registration Desk
Registration can be found in front of the entrance to the Grand Ballroom.

Name Badges
For security purposes all attendees must wear their name badge at all times in the meeting venue. If you misplace your name badge, please advise staff at the registration desk.

Wi-Fi Availability
Free wi-fi is available to all attendees. The passcode will be posted at the meeting.

Catering
Breakfast and lunch will be served in the Grand Ballroom Foyer. Tea and coffee will be available during the breaks.

Parking
Self-parking and valet parking at the Sheraton Vancouver Wall Centre is available, please contact the Sheraton Vancouver Wall Centre for rates. Alternatively, there are options for meter parking and off-street parking (above and under ground) nearby.

Smoking
This conference has a no smoking policy.

Mobile Devices
As a courtesy to all delegates and speakers set your mobile devices to silent during all sessions.

Twitter
You can follow concurrent sessions and general commentary on Twitter using the hashtag #ACureForAll. You can also follow all IAS 2015 tweets with #IAS2015.

Welcome Drinks
Welcome drinks will be held in the Grand Ballroom Foyer of the Sheraton Vancouver Wall Centre on Friday, July 17 from 5 p.m. to 6 p.m.

www.coinfectionmeeting.com
8:00 - 8:45 a.m.

Registration & continental breakfast in Grand Ballroom Foyer

8:45 - 10:30 a.m.

HCV therapeutic development and access

Chairs: Marina Klein & Greg Dore

Room: Ballroom A & B

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:45 - 9:00 a.m.</td>
<td>Introductions</td>
<td>Marina Klein (Canada)</td>
</tr>
<tr>
<td>9:00 - 9:30 a.m.</td>
<td>Global HIV/viral hepatitis co-infection: epidemic trends and disease burden</td>
<td>Massimo Ghidinelli (WHO)</td>
</tr>
<tr>
<td>9:30 - 10:00 a.m.</td>
<td>Implementation of modern HCV therapy into clinical practice</td>
<td>Jordan Feld (Canada)</td>
</tr>
<tr>
<td>10:00 - 10:30 a.m.</td>
<td>Right to care: in resource limited and high income settings</td>
<td>Niklas Luhmann (Médecins du Monde)</td>
</tr>
</tbody>
</table>

10:30 - 11:00 a.m.

Break in Grand Ballroom Foyer (refreshments provided)

11:00 - 12:30 p.m.

Prevention of viral hepatitis: Which strategies will work?

Chairs: Natasha Martin & Gail Matthews

Room: Ballroom A & B

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 - 11:30 a.m.</td>
<td>Antiviral prevention: treatment, PEP, PrEP</td>
<td>Greg Dore (Australia)</td>
</tr>
<tr>
<td>11:30 - 12:00 p.m.</td>
<td>PMTC for viral hepatitis</td>
<td>Lawrence Mbuagbaw (Canada)</td>
</tr>
<tr>
<td>12:00 - 12:30 p.m.</td>
<td>Modelling the impact of increased testing and treatment on the HCV epidemic</td>
<td>Homie Razavi (CDA, USA)</td>
</tr>
</tbody>
</table>

12:30 - 1:30 p.m.

Lunch in Grand Ballroom Foyer

1:30 - 3:00 p.m.

Optimizing HCV treatment costs and outcomes

Chairs: Jens Lundgren & Mauro Schechter

Room: Ballroom A & B
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 - 2:00 p.m.</td>
<td>The minimum cost to cure HCV with DAAs revisited</td>
<td>Andrew Hill (UK)</td>
<td>Room: Ballroom A &amp; B</td>
</tr>
<tr>
<td>2:00 - 2:30 p.m.</td>
<td>Can pricing strategies make a difference: The Brazil experience</td>
<td>Fabio Mesquita (Brazil)</td>
<td>Room: Ballroom A &amp; B</td>
</tr>
<tr>
<td>2:30 - 3:00 p.m.</td>
<td>Impact of HCV cure on non-hepatic comorbidities</td>
<td>Gail Matthews (Australia)</td>
<td>Room: Ballroom A &amp; B</td>
</tr>
<tr>
<td>3:00 - 3:30 p.m.</td>
<td>Break</td>
<td></td>
<td>Room: Ballroom A &amp; B</td>
</tr>
<tr>
<td>3:30 - 5:00 p.m.</td>
<td>Hepatitis prevention and implementation (IAS 2015 abstracts)</td>
<td>Chairs: Natasha Martin &amp; Ying-Ru Lo</td>
<td>Room: Ballroom C &amp; D</td>
</tr>
<tr>
<td>3:30 - 5:00 p.m.</td>
<td>HCV pathogenesis and therapeutic development (IAS 2015 abstracts)</td>
<td>Chairs: Marina Klein &amp; Jürgen Rockstroh</td>
<td>Room: Ballroom A &amp; B</td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td>P. Easterbrook - Global systematic review and meta-analysis of the seroprevalence of HBV and HCV infection in HIV-infected persons</td>
<td></td>
<td>Room: Ballroom A &amp; B</td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td>N. Martin – The impact of serosorting on hepatitis C and HIV coinfection amongst MSM: a modelling analysis</td>
<td></td>
<td>Room: Ballroom A &amp; B</td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td>E. Huchet – Low incidence of reinfection with hepatitis C virus after successful treatment in Montreal</td>
<td></td>
<td>Room: Ballroom A &amp; B</td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td>F. Jean – Discovery of a novel class of naturally occurring indirect-acting antiviral agents against both HIV-1 and hepatitis C virus infection</td>
<td></td>
<td>Room: Ballroom A &amp; B</td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td>C. Down – The risk of cardiovascular disease and death over 10 years in HIV/HCV co-infected patients with and without steatosis</td>
<td></td>
<td>Room: Ballroom A &amp; B</td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td>D. Wyles – High efficacy and low relapse rates observed with 8 or 12 weeks of LDV/SOF STR in GT1 HCV infected treatment-naive, non-cirrhotic patients with retreatment HCV RNA &lt; 6 Million IU/mL</td>
<td></td>
<td>Room: Ballroom A &amp; B</td>
</tr>
<tr>
<td>4:30 - 5:00 p.m.</td>
<td>Panel discussion</td>
<td></td>
<td>Room: Ballroom A &amp; B</td>
</tr>
<tr>
<td>4:30 - 5:00 p.m.</td>
<td>Panel discussion</td>
<td></td>
<td>Room: Ballroom A &amp; B</td>
</tr>
<tr>
<td>5:00 - 6:00 p.m.</td>
<td>Welcome drinks in Grand Ballroom Foyer</td>
<td></td>
<td>Room: Ballroom A &amp; B</td>
</tr>
</tbody>
</table>
8:00 a.m. - 9:00 a.m.

Continental breakfast in Grand Ballroom Foyer

9:00 - 10:30 a.m.

Hot topics in HBV

Chairs: Sai Subhasree Raghavan & Pierre Côté
Room: Ballroom A & B

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 - 9:30 a.m.</td>
<td>HBV cure agenda: How far along are we?</td>
<td>Marion Peters (USA)</td>
</tr>
<tr>
<td>9:30 - 10:00 a.m.</td>
<td>Scaling up HBV testing &amp; treatment: Challenges and successes</td>
<td>Monique Andersson (S. Africa)</td>
</tr>
<tr>
<td>10:00 - 10:30 a.m.</td>
<td>Does HBV DNA suppression reduce the risk of HCC?</td>
<td>Henry Chan (Hong Kong)</td>
</tr>
</tbody>
</table>

10:30 - 11:00 a.m.

Break in Grand Ballroom Foyer (refreshments provided)

11:00 - 12:30 p.m.

Complex issues in viral hepatitis management

Chairs: Curtis Cooper & Christoph Boesecke
Room: Ballroom A & B

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 - 11:30 a.m.</td>
<td>How short is short enough: optimal duration for HCV treatment</td>
<td>Sanjay Bhagani (UK)</td>
</tr>
<tr>
<td>11:30 - 12:00 p.m.</td>
<td>Will resistance matter in the end?</td>
<td>Jean Michel Pawlotsky (France)</td>
</tr>
<tr>
<td>12:00 - 12:30 p.m.</td>
<td>Do we already have solutions for all genotypes?</td>
<td>Peter Ghali (Canada)</td>
</tr>
</tbody>
</table>

12:30 - 1:30 p.m.

Lunch in Grand Ballroom Foyer

1:30 - 3:00 p.m.

Workshop – A focus on people who inject drugs
Moderators: Tracy Swan & Alissa Greer
Room: Ballroom A & B

Workshop – Challenges and opportunities for scaling up viral hepatitis programs in low and middle and high income countries
Moderators: Anchalee Avihingsanon & Mark Hull
Room: Ballroom C & D
1:35 - 1:50 p.m.  The role of drug policy in the HCV epidemic  Dan Werb (Canada)  

1:50 - 1:55 p.m.  Test and treat for HCV in PWID  Jason Grebely (Australia)  

1:55 - 2:15 p.m.  Mongolia  Wilbert Bannenberg (Netherlands)  

2:05 - 2:20 p.m.  Linking HCV treatment to addiction care  Julie Bruneau (Canada)  

2:15 - 2:35 p.m.  Wellness through continuity: First Peoples in Canada, HIV and hepatitis C  Alexandra King (Canada)  

2:20 - 3:05 p.m.  Panel discussion  Chairs and a community member  

3:05 - 3:30 p.m.  Break in Grand Ballroom Foyer (refreshments provided)  

3:30 - 6:00 p.m.  Public health advocacy and access to HCV therapy  

Chairs: Isabelle Andrieux-Meyer & Tracy Swan  
Room: Ballroom A & B  

3:30 - 3:45 p.m.  Community-based organizations role in global advocacy for HCV therapy  Karyn Kaplan (TAG)  

3:45 - 4:00 p.m.  Implementation of HBV HCV programs in resource limited settings: MSF operational update  Isabelle Andrieux-Meyer (MSF)  

4:00 - 4:15 p.m.  HBV & HCV eradications strategies for 2030  Andrew Ball (WHO)  

4:15 – 5:30 p.m.  Panel discussion: Pushing the viral hepatitis eradication agenda forward  
Moderator: Kathryn Gretsinger (CBC)  Key questions:  
1. What are the most significant access barriers to overcome?  
2. What are your plans to address it?  
Isabelle Andrieux-Meyer (MSF)  Andrew Ball (WHO)  Wilbert Bannenberg (HERA)  Herb Harwell (Clinton Health Access)  Mark Lallemant (DNDi)  Priti Radhakrishnan (I-MAK)  Tracy Swan (TAG)  

5:30 - 5:45 p.m.  Audience questions  

5:45 – 6:00 p.m.  Closing Remarks  Jürgen Rockstroh (Germany)
2nd International HIV/Viral Hepatitis Co-infection Meeting

The 2nd International HIV/Viral Hepatitis Co-infection Meeting is an official event of the 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015).

Logistics for the meeting are being managed by the CIHR Canadian HIV Trials Network.

CIHR Canadian HIV Trials Network
588 – 1081 Burrard Street
Vancouver, BC V6Z 1Y6, Canada
Telephone: +1 (604) 806-8327
Toll Free in N. America: +1 (800) 661-4664
Email: ctninfo@hivnet.ubc.ca
Web: www.hivnet.ubc.ca